SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:lup.lub.lu.se:4b0485ff-ed3c-442d-80fd-a4981e817a70"
 

Sökning: onr:"swepub:oai:lup.lub.lu.se:4b0485ff-ed3c-442d-80fd-a4981e817a70" > Real-World Six- and...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00006650naa a2200733 4500
001oai:lup.lub.lu.se:4b0485ff-ed3c-442d-80fd-a4981e817a70
003SwePub
008221227s2022 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:149432037
0247 a https://lup.lub.lu.se/record/4b0485ff-ed3c-442d-80fd-a4981e817a702 URI
0247 a https://doi.org/10.1002/acr.245602 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1494320372 URI
040 a (SwePub)lud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a art2 swepub-publicationtype
072 7a ref2 swepub-contenttype
1001 a Michelsen, Brigitteu Copenhagen University Hospital4 aut
2451 0a Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries
264 c 2022-04-29
264 1b Wiley,c 2022
300 a 14 s.
520 a Objective: There is a lack of real-life studies on interleukin-17 (IL-17) inhibition in psoriatic arthritis (PsA). We assessed real-life 6- and 12-month effectiveness (i.e., retention, remission, low disease activity [LDA], and response rates) of the IL-17 inhibitor secukinumab in PsA patients overall and across 1) number of prior biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs), 2) years since diagnosis, and 3) European registries. Methods: Thirteen quality registries in rheumatology participating in the European Spondyloarthritis Research Collaboration Network provided longitudinal, observational data collected as part of routine care for secondary use. Data were pooled and analyzed with Kaplan-Meier plots, log rank tests, Cox regression, and multiple linear and logistic regression analyses. Results: A total of 2,017 PsA patients started treatment with secukinumab between 2015 and 2018. Overall secukinumab retention rates were 86% and 76% after 6 and 12 months, respectively. Crude (LUNDEX adjusted) 6-month remission/LDA (LDA including remission) rates for the 28-joint Disease Activity Index for Psoriatic Arthritis, the Disease Activity Score in 28 joints using the C-reactive protein level, and the Simplified Disease Activity Index (SDAI) were 13%/46% (11%/39%), 36%/55% (30%/46%), and 13%/56% (11%/47%), and 12-month rates were 11%/46% (7%/31%), 39%/56% (26%/38%), and 16%/62% (10%/41%), respectively. Clinical Disease Activity Index remission/LDA rates were similar to the SDAI rates. Six-month American College of Rheumatology 20%/50%/70% improvement criteria responses were 34%/19%/11% (29%/16%/9%); 12-month rates were 37%/21%/11% (24%/14%/7%). Secukinumab effectiveness was significantly better for b/tsDMARD-naive patients, similar across time since diagnosis (<2/2–4/>4 years), and varied significantly across the European registries. Conclusion: In this large real-world study on secukinumab treatment in PsA, 6- and 12-month effectiveness was comparable to that in previous observational studies of tumor necrosis factor inhibitors. Retention, remission, LDA, and response rates were significantly better for b/tsDMARD-naive patients, were independent of time since diagnosis, and varied significantly across the European countries.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Reumatologi och inflammation0 (SwePub)302102 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Rheumatology and Autoimmunity0 (SwePub)302102 hsv//eng
7001 a Georgiadis, Stylianosu Copenhagen University Hospital4 aut
7001 a Di Giuseppe, Danielau Karolinska Institutet,Karolinska Institute4 aut
7001 a Loft, Anne G.u Aarhus University Hospital4 aut
7001 a Nissen, Michael J.u Geneva University Hospital4 aut
7001 a Iannone, Florenzou University of Bari Aldo Moro4 aut
7001 a Pombo-Suarez, Manuelu Complejo Hospitalario Universitario de Santiago4 aut
7001 a Mann, Hermanu Charles University in Prague4 aut
7001 a Rotar, Zigau University Medical Centre Ljubljana4 aut
7001 a Eklund, Kari K.u Helsinki University Central Hospital4 aut
7001 a Kvien, Tore K.u Diakonhjemmet Hospital4 aut
7001 a Santos, Maria J.u University of Lisbon4 aut
7001 a Gudbjornsson, Bjornu University of Iceland4 aut
7001 a Codreanu, Catalinu Carol Davila University of Medicine and Pharmacy4 aut
7001 a Yilmaz, Semau Selcuk University4 aut
7001 a Wallman, Johan K.u Lund University,Lunds universitet,Reumatologi och molekylär skelettbiologi,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Lund Arthritis Research Group (LARG),Forskargrupper vid Lunds universitet,Rheumatology,Section III,Department of Clinical Sciences, Lund,Faculty of Medicine,Lund University Research Groups,Skåne University Hospital4 aut0 (Swepub:lu)med-jnk
7001 a Brahe, Cecilie H.u Copenhagen University Hospital4 aut
7001 a Möller, Burkhardu Bern University Hospital4 aut
7001 a Favalli, Ennio G.4 aut
7001 a Sánchez-Piedra, Carlos4 aut
7001 a Nekvindova, Lucieu Charles University in Prague4 aut
7001 a Tomsic, Matijau University Medical Centre Ljubljana4 aut
7001 a Trokovic, Ninau Helsinki University Central Hospital4 aut
7001 a Kristianslund, Eirik K.u Diakonhjemmet Hospital4 aut
7001 a Santos, Helenau Portuguese Institute of Rheumatology4 aut
7001 a Löve, Thorvardur J.u University of Iceland4 aut0 (Swepub:lu)th0128lo
7001 a Ionescu, Ruxandrau Carol Davila University of Medicine and Pharmacy4 aut
7001 a Pehlivan, Yavuzu Uludağ University4 aut
7001 a Jones, Gareth T.u University of Aberdeen4 aut
7001 a van der Horst-Bruinsma, Ireneu Academic Medical Center of University of Amsterdam (AMC)4 aut
7001 a Ørnbjerg, Lykke M.u Copenhagen University Hospital4 aut
7001 a Østergaard, Mikkelu University of Copenhagen4 aut
7001 a Hetland, Merete L.u University of Copenhagen4 aut
7102 a Karolinska Instituteb Copenhagen University Hospital4 org
7730 t Arthritis Care and Researchd : Wileyg 74:7, s. 1205-1218q 74:7<1205-1218x 2151-464Xx 2151-4658
8564 u http://dx.doi.org/10.1002/acr.24560x freey FULLTEXT
8564 u https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/acr.24560
8564 8u https://lup.lub.lu.se/record/4b0485ff-ed3c-442d-80fd-a4981e817a70
8564 8u https://doi.org/10.1002/acr.24560
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:149432037

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy